Pharmacokinetics and biodistribution of genetically engineered antibodies

Surinder Kumar Batra, Maneesh Jain, Uwe A. Wittel, Subhash C. Chauhan, David Colcher

Research output: Contribution to journalReview article

140 Citations (Scopus)

Abstract

The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.

Original languageEnglish (US)
Pages (from-to)603-608
Number of pages6
JournalCurrent Opinion in Biotechnology
Volume13
Issue number6
DOIs
StatePublished - Dec 1 2002

Fingerprint

Pharmacokinetics
Antibodies
Tumors
Radioimmunotherapy
Neoplasms
Monoclonal antibodies
Antigens
Drug products
Monoclonal Antibodies
Tissue
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Pharmacokinetics and biodistribution of genetically engineered antibodies. / Batra, Surinder Kumar; Jain, Maneesh; Wittel, Uwe A.; Chauhan, Subhash C.; Colcher, David.

In: Current Opinion in Biotechnology, Vol. 13, No. 6, 01.12.2002, p. 603-608.

Research output: Contribution to journalReview article

Batra, Surinder Kumar ; Jain, Maneesh ; Wittel, Uwe A. ; Chauhan, Subhash C. ; Colcher, David. / Pharmacokinetics and biodistribution of genetically engineered antibodies. In: Current Opinion in Biotechnology. 2002 ; Vol. 13, No. 6. pp. 603-608.
@article{0773a7862b6e4454ae1159b551b7e4a0,
title = "Pharmacokinetics and biodistribution of genetically engineered antibodies",
abstract = "The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.",
author = "Batra, {Surinder Kumar} and Maneesh Jain and Wittel, {Uwe A.} and Chauhan, {Subhash C.} and David Colcher",
year = "2002",
month = "12",
day = "1",
doi = "10.1016/S0958-1669(02)00352-X",
language = "English (US)",
volume = "13",
pages = "603--608",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics and biodistribution of genetically engineered antibodies

AU - Batra, Surinder Kumar

AU - Jain, Maneesh

AU - Wittel, Uwe A.

AU - Chauhan, Subhash C.

AU - Colcher, David

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.

AB - The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.

UR - http://www.scopus.com/inward/record.url?scp=0036898144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036898144&partnerID=8YFLogxK

U2 - 10.1016/S0958-1669(02)00352-X

DO - 10.1016/S0958-1669(02)00352-X

M3 - Review article

C2 - 12482521

AN - SCOPUS:0036898144

VL - 13

SP - 603

EP - 608

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

IS - 6

ER -